ClinicalTrials.gov
ClinicalTrials.gov Menu

Civamide Nasal Solution for Cluster Headache (ECH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01341548
Recruitment Status : Not yet recruiting
First Posted : April 25, 2011
Last Update Posted : May 3, 2018
Sponsor:
Information provided by (Responsible Party):
Winston Laboratories

April 22, 2011
April 25, 2011
May 3, 2018
November 2019
November 2021   (Final data collection date for primary outcome measure)
The Percent Change in the Number of Cluster Headaches per Week from Baseline to Weeks 1 through 3 of the Post-Treatment Observation Period for the Modified Intent-to-Treat Population [ Time Frame: Weeks 1 - 3 of the Post-Treatment Observation Period ]
Same as current
Complete list of historical versions of study NCT01341548 on ClinicalTrials.gov Archive Site
  • The Percent Change in the Number of Cluster Headaches per Week from Baseline to Weeks 1 through 3 of the Post-Treatment Observation Period for the Intent-to-Treat and Per Protocol Populations [ Time Frame: Weeks 1 - 3 of the Post-Treatment Observation Period ]
  • The Percent Change in the Number of Cluster Headaches per Week from Baseline to Individual Weeks 1, 2, and 3 of the Post-Treatment Observation Period for the Modified Intent-to-Treat and the Per Protocol Populations [ Time Frame: Individual Weeks 1, 2 and 3 of the Post-Treatment Observation Period ]
  • The Change in the Number of Cluster Headaches per Week from Baseline to Weeks 1 through 3 and to Individual Weeks 1, 2, and 3 for the Post-Treatment Observation Period for the Modified Intent-to-Treat and the Per Protocol Populations [ Time Frame: Weeks 1 - 3 and to Individual Weeks 1, 2, and 3 for the Post-Treatment Observation Period ]
Same as current
Not Provided
Not Provided
 
Civamide Nasal Solution for Cluster Headache
A Phase III, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group, Multicenter Evaluation of Civamide Nasal Solution 0.01% in the Prevention of Cluster Headaches During an Episodic Cluster Headache Period
The purpose of this study is to evaluate the safety and efficacy of intranasally administered civamide nasal solution in the prevention of cluster headaches during an episodic cluster headache period.

This is a double-blind, randomized, vehicle-controlled, parallel-group, multi-center, phase III efficacy and safety study of civamide nasal solution 0.01% in the prevention of cluster headaches during an episodic cluster headache period. Approximately 180 subjects (about 90 per treatment group),will be enrolled and randomized to double-blind treatment with either civamide nasal solution 0.01% or vehicle solution at approximately 50 study sites with about 2-5 subjects randomized per enrolling site.

This study consists of four periods beginning with a Screening Period, lasting for a minimum of 1 day to a maximum of 12 months, during which a subject previously diagnosed with episodic cluster headaches is not experiencing cluster headaches and is awaiting the onset of their next episodic cluster headache period and subsequent enrollment. The Screening Period is followed by a 31-day study, consisting of a 3-day Baseline Period which may begin with the onset of an episodic cluster headache period and ends on the day prior to initiating treatment (Day -1). Subjects return for Visit 2 (Day 1, Pre-Dose) and the Treatment Period begins, consisting of seven (7) days of double-blind treatment. The Treatment Period is immediately followed by a twenty-one (21) day Post-Treatment Observation Period.

Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Episodic Cluster Headache
Drug: Civamide nasal solution 0.01%
20ug/dose, BID for 7 days 0.1 ml to each nostril
  • Active Comparator: Civamide Nasal Solution 0.01%
    Intervention: Drug: Civamide nasal solution 0.01%
  • Placebo Comparator: Vehicle Solution
    Intervention: Drug: Civamide nasal solution 0.01%
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
180
Same as current
February 2022
November 2021   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Written IRB-approved informed consent has been obtained and signed, within 12 months of entering into the Baseline Period (Day -3).
  • Male or female 18 years or older.
  • Subject has ≥2 year history of episodic cluster headache with at least 2 previous episodic cluster headache periods.
  • Cluster Headaches must meet the following International Headache Society Diagnostic Criteria :

    • Severe, unilateral, orbital, superorbital and/or temporal pain lasting 15 to 180 minutes untreated.
    • Headache is associated with at least one of the following which have to be present on the side of the pain:

      • Conjunctival injection
      • Lacrimation
      • Nasal Congestion
      • Rhinorrhea
      • Forehead and facial sweating
      • Miosis
      • Ptosis
      • Eyelid edema or
      • A sense of restlessness or agitation
  • The current episodic cluster headache period is expected to last at least 5 weeks but no more than 24 weeks from the time of entry into the Baseline Period (Day -3), based on the average duration of the subject's usual episodic cluster headache period.
  • At least one cluster headache (but no more than 8) daily on each of the three days of the Baseline Period (Days -3, -2, -1) immediately preceding Study Day 1.
  • The subject is in generally good health, other than history of episodic cluster headache.
  • The subject agrees not to begin any new concurrent medications or restricted medications during their participation in study.
  • All females of childbearing potential must have a negative urine and/or serum pregnancy test prior to entry into the Treatment Period.
  • Females of childbearing potential agree to use an approved form of birth control or to abstain from sexual activity during the study.
  • Subject can read and write in the local language and can be expected to reliably follow study procedures.

Exclusion Criteria:

  • Clinical, historical or previous laboratory evidence of significant cardiovascular, renal, gastrointestinal, pulmonary, hepatic, endocrine, neurological (not including cluster headaches), psychological, or other systemic disease that, in the opinion of the investigator, might confound the results of the study or pose an additional risk to the subject.
  • Presence of a significant nasal disorder.
  • Initiation of a medication, discontinuation of a medication or a change in the regimen of existing medication(s) or therapies for prophylaxis of cluster headaches in the 17 days prior to entering the Treatment Period (Study Day 1).
  • Use of systemic steroids to treat the current cluster headache episode.
  • Use of restricted medications/treatments within the given time period prior to the Treatment Period and throughout the study (Table 1 of Protocol)
  • Subject has difficulty distinguishing his/her episodic cluster headache attacks from other types of headaches, such as tension type headaches.
  • Presence of chronic paroxysmal hemicrania, transformed migraine, or analgesic rebound headaches.
  • Females who are pregnant, breast-feeding, or planning to become pregnant during the study.
  • Subject has a history of alcohol and/or drug abuse within 12 months prior to the Screening Visit..
  • Subject has known hypersensitivity to or contraindication to the use of civamide, capsaicin, or to any excipient of the clinical formulation.
  • Subject has participated in another investigational study or taken another investigational drug within the past 4 weeks.
  • Subject has participated in prior efficacy studies of intranasal civamide: WL-1001-02-01, WL-1001-02-02, WL-1001-02-03 or WL-1001-02-05. (This does not include any subject who entered the screening period for study WL-1001-02-01, WL-1001-02-02, WL-1001-02-03 or WL-1001-02-05 but did not randomize to treatment).
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
No
Contact: Heidi B Fezatte, BS 847-362-8200 heidi@winstonlabs.com
Contact: Scott B Phillips, MD 847-362-8200 scott@winstonlabs.com
Not Provided
 
 
NCT01341548
WL-1001-02-06
No
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Plan to Share IPD: No
Winston Laboratories
Winston Laboratories
Not Provided
Study Director: Scott B Phillips, M.D. Winston Laboratories
Winston Laboratories
May 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP